16">The study aims to determine the effectiveness of SerpinPC in reducing bleeds in individuals with hemophilia B. Hemophilia B is a rare genetic disorder that affects the blood's ability to clot properly, leading to prolonged bleeding and increased risk of complications. Current treatment options for hemophilia B include regular infusions of clotting factors, but these can be costly and time-consuming.
Centessa Pharmaceuticals plc believes that SerpinPC has the potential to revolutionize the treatment landscape for hemophilia B. Unlike traditional clotting factor replacement therapies, SerpinPC is an investigational subcutaneously administered inhibitor of activated protein C (APC). This unique mechanism of action could offer a more convenient and effective treatment option for individuals with hemophilia B.
The company's PRESent-2 study will play a crucial role in determining the safety and efficacy of SerpinPC. By evaluating its impact on treated bleeds compared to the observation period before starting treatment, researchers hope to gather valuable insights into how this therapy can improve outcomes for individuals with hemophilia